TECON BIOLOGY Co.LTD (SHE:002100)
China
· Delayed Price · Currency is CNY 7.84
+0.13 (1.69%)
Apr 29, 2026, 3:04 PM CST
TECON BIOLOGY Co.LTD Income Statement
Financials in millions CNY. Fiscal year is January - December.
Millions CNY. Fiscal year is Jan - Dec.
Fiscal Year | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | 2020 - 2016 |
|---|---|---|---|---|---|---|
Period Ending | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Jan '23 Jan 1, 2023 | Jan '22 Jan 1, 2022 | 2021 - 2017 |
| Operating Revenue | 16,981 | 17,114 | 18,973 | 16,958 | 15,663 | Upgrade
|
| Other Revenue | - | 62.23 | 52.75 | 31.07 | 47.43 | Upgrade
|
| Revenue | 16,981 | 17,176 | 19,026 | 16,989 | 15,711 | Upgrade
|
| Revenue Growth (YoY) | -1.13% | -9.72% | 11.99% | 8.14% | 31.07% | Upgrade
|
| Cost of Revenue | 15,306 | 15,103 | 18,965 | 15,375 | 14,595 | Upgrade
|
| Gross Profit | 1,675 | 2,073 | 61.29 | 1,615 | 1,116 | Upgrade
|
| Selling, General & Admin | 898.44 | 989.66 | 1,030 | 971.45 | 1,340 | Upgrade
|
| Research & Development | 183.51 | 194.2 | 252.85 | 176.38 | 167.89 | Upgrade
|
| Other Operating Expenses | -10.23 | 45.81 | 46.8 | 38.72 | 38.33 | Upgrade
|
| Operating Expenses | 1,072 | 1,254 | 1,347 | 1,237 | 1,570 | Upgrade
|
| Operating Income | 602.98 | 818.1 | -1,286 | 377.63 | -454.1 | Upgrade
|
| Interest Expense | - | -178.94 | -245.54 | -248.55 | -206.09 | Upgrade
|
| Interest & Investment Income | 33.83 | 38.64 | 60.94 | 64.94 | 46.99 | Upgrade
|
| Currency Exchange Gain (Loss) | - | -0 | - | - | - | Upgrade
|
| Other Non Operating Income (Expenses) | -264 | -99.29 | -39.41 | -5.87 | -1.9 | Upgrade
|
| EBT Excluding Unusual Items | 372.81 | 578.52 | -1,510 | 188.14 | -615.1 | Upgrade
|
| Impairment of Goodwill | - | -12.66 | -9.58 | - | - | Upgrade
|
| Gain (Loss) on Sale of Investments | 0.81 | -1.87 | -0 | 0.94 | - | Upgrade
|
| Gain (Loss) on Sale of Assets | 0.59 | 4.5 | 3.9 | 0.23 | -36.72 | Upgrade
|
| Asset Writedown | -46.1 | -28.91 | -34.12 | -0.06 | -48.63 | Upgrade
|
| Other Unusual Items | - | 71.23 | 56.63 | 26.79 | 37 | Upgrade
|
| Pretax Income | 328.11 | 610.81 | -1,493 | 216.03 | -663.45 | Upgrade
|
| Income Tax Expense | 27.8 | 14.39 | 23.46 | 26.03 | 31.9 | Upgrade
|
| Earnings From Continuing Operations | 300.31 | 596.42 | -1,516 | 190 | -695.35 | Upgrade
|
| Minority Interest in Earnings | -89.67 | 8.63 | 153.11 | 90.78 | -7.45 | Upgrade
|
| Net Income | 210.63 | 605.05 | -1,363 | 280.78 | -702.79 | Upgrade
|
| Net Income to Common | 210.63 | 605.05 | -1,363 | 280.78 | -702.79 | Upgrade
|
| Net Income Growth | -65.19% | - | - | - | - | Upgrade
|
| Shares Outstanding (Basic) | 1,404 | 1,375 | 1,350 | 1,337 | 1,098 | Upgrade
|
| Shares Outstanding (Diluted) | 1,404 | 1,375 | 1,350 | 1,337 | 1,098 | Upgrade
|
| Shares Change (YoY) | 2.12% | 1.88% | 0.95% | 21.76% | 2.13% | Upgrade
|
| EPS (Basic) | 0.15 | 0.44 | -1.01 | 0.21 | -0.64 | Upgrade
|
| EPS (Diluted) | 0.15 | 0.44 | -1.01 | 0.21 | -0.64 | Upgrade
|
| EPS Growth | -65.91% | - | - | - | - | Upgrade
|
| Free Cash Flow | 1.91 | 535.4 | 750.48 | -1,102 | -219.37 | Upgrade
|
| Free Cash Flow Per Share | 0.00 | 0.39 | 0.56 | -0.82 | -0.20 | Upgrade
|
| Dividend Per Share | - | 0.220 | - | 0.220 | - | Upgrade
|
| Gross Margin | 9.86% | 12.07% | 0.32% | 9.50% | 7.11% | Upgrade
|
| Operating Margin | 3.55% | 4.76% | -6.76% | 2.22% | -2.89% | Upgrade
|
| Profit Margin | 1.24% | 3.52% | -7.17% | 1.65% | -4.47% | Upgrade
|
| Free Cash Flow Margin | 0.01% | 3.12% | 3.94% | -6.49% | -1.40% | Upgrade
|
| EBITDA | 1,262 | 1,525 | -482.87 | 1,091 | 250.85 | Upgrade
|
| EBITDA Margin | 7.43% | 8.88% | -2.54% | 6.42% | 1.60% | Upgrade
|
| D&A For EBITDA | 658.94 | 706.76 | 802.92 | 713.19 | 704.95 | Upgrade
|
| EBIT | 602.98 | 818.1 | -1,286 | 377.63 | -454.1 | Upgrade
|
| EBIT Margin | 3.55% | 4.76% | -6.76% | 2.22% | -2.89% | Upgrade
|
| Effective Tax Rate | 8.47% | 2.36% | - | 12.05% | - | Upgrade
|
| Revenue as Reported | - | 17,176 | 19,026 | 16,989 | 15,711 | Upgrade
|
Source: S&P Capital IQ. Standard template. Financial Sources.